메뉴 건너뛰기




Volumn 1478, Issue , 2012, Pages 55-63

Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats

Author keywords

Age related macular degeneration; Apoptosis; Bevacizumab; Retinal ganglion cell (RGC)

Indexed keywords

BALANCED SALT SOLUTION; BEVACIZUMAB; LIPOCORTIN 5;

EID: 84866511447     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.08.014     Document Type: Article
Times cited : (37)

References (35)
  • 2
    • 77649324295 scopus 로고    scopus 로고
    • Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections
    • R.A. Adelman, Q. Zheng, and H.R. Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J. Ocul. Pharmacol. Ther. 26 2010 105 110
    • (2010) J. Ocul. Pharmacol. Ther. , vol.26 , pp. 105-110
    • Adelman, R.A.1    Zheng, Q.2    Mayer, H.R.3
  • 3
    • 70349449737 scopus 로고    scopus 로고
    • Introduction: Understanding the role of angiogenesis and anti-angiogenic agents in age-related macular degeneration
    • S.B. Blessler Introduction: understanding the role of angiogenesis and anti-angiogenic agents in age-related macular degeneration Ophthalmology 116 2009 S1 S7
    • (2009) Ophthalmology , vol.116
    • Blessler, S.B.1
  • 4
    • 77149166301 scopus 로고    scopus 로고
    • Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells
    • S.V. Brar, R.K. Sharma, R.K. Murthy, and K.V. Chalam Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells J. Ocul. Pharmacol. Ther. 25 2009 507 511
    • (2009) J. Ocul. Pharmacol. Ther. , vol.25 , pp. 507-511
    • Brar, S.V.1    Sharma, R.K.2    Murthy, R.K.3    Chalam, K.V.4
  • 5
    • 77956968916 scopus 로고    scopus 로고
    • Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells
    • S.V. Brar, R.K. Sharma, R.K. Murthy, and K.V. Chalam Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells Mol. Vis. 16 2010 1848 1853
    • (2010) Mol. Vis. , vol.16 , pp. 1848-1853
    • Brar, S.V.1    Sharma, R.K.2    Murthy, R.K.3    Chalam, K.V.4
  • 6
    • 38449095942 scopus 로고    scopus 로고
    • Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment
    • C.K. Chan, and S.G. Lin Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment Eur. J. Ophthalmol. 17 2007 674 676
    • (2007) Eur. J. Ophthalmol. , vol.17 , pp. 674-676
    • Chan, C.K.1    Lin, S.G.2
  • 7
    • 67749116153 scopus 로고    scopus 로고
    • Bevacizumab is not toxic to retinal ganglion cells after repated intravitreal injection
    • C.K. Cheng, P.H. Peng, L.T. Tien, Y.J. Cai, C.F. Chen, and Y.J. Lee Bevacizumab is not toxic to retinal ganglion cells after repated intravitreal injection Retina 29 2009 306 312
    • (2009) Retina , vol.29 , pp. 306-312
    • Cheng, C.K.1    Peng, P.H.2    Tien, L.T.3    Cai, Y.J.4    Chen, C.F.5    Lee, Y.J.6
  • 8
    • 2442621619 scopus 로고    scopus 로고
    • Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    • N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400
    • (2004) Nat. Rev. Drug Discov. , vol.3 , pp. 391-400
    • Ferrara, N.1    Hillan, K.J.2    Gerber, H.P.3    Novotny, W.4
  • 9
    • 33749632278 scopus 로고    scopus 로고
    • Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    • N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
    • (2006) Retina , vol.26 , pp. 859-870
    • Ferrara, N.1    Damico, L.2    Shams, N.3    Lowman, H.4    Kim, R.5
  • 11
    • 81755161510 scopus 로고    scopus 로고
    • Protective effect of Bax ablation against cell loss in the retinal ganglion layer induced by optic nerve crush in transgenic mice
    • N. Goldenberg-Cohen, O. Dratviman-Storobinsky, Dadon Bar El, S. Cheporko, and Y. Hochhauser, E. Protective effect of Bax ablation against cell loss in the retinal ganglion layer induced by optic nerve crush in transgenic mice J. Neuroophthalmol. 31 2011 331 338
    • (2011) J. Neuroophthalmol. , vol.31 , pp. 331-338
    • Goldenberg-Cohen, N.1    Dratviman-Storobinsky, O.2    El, D.B.3    Cheporko, S.4    Hochhauser, E.Y.5
  • 13
    • 80052771986 scopus 로고    scopus 로고
    • Visual results following intravitreal bevacizumab in neovascular age-related macular degeneration
    • K. Iqbal, J. Baig, A.Z. Jamil, H. Jamil, K. Mirza, and T. Khan Visual results following intravitreal bevacizumab in neovascular age-related macular degeneration J. Coll. Physicians Surg. Pak. 21 2011 535 538
    • (2011) J. Coll. Physicians Surg. Pak. , vol.21 , pp. 535-538
    • Iqbal, K.1    Baig, J.2    Jamil, A.Z.3    Jamil, H.4    Mirza, K.5    Khan, T.6
  • 14
    • 34548331324 scopus 로고    scopus 로고
    • Effect of anti-VEGF antibody on retinal ganglion cell in rats
    • A. Iriyama, Y.N. Chen, Y. Tamaki, and Y. Yanagi Effect of anti-VEGF antibody on retinal ganglion cell in rats Br. J. Ophthalmol. 91 2007 1230 1233
    • (2007) Br. J. Ophthalmol. , vol.91 , pp. 1230-1233
    • Iriyama, A.1    Chen, Y.N.2    Tamaki, Y.3    Yanagi, Y.4
  • 15
    • 77956058023 scopus 로고    scopus 로고
    • In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells
    • M.Y. Kahook, and D.A. Ammar In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells J. Glaucoma 19 2010 437 441
    • (2010) J. Glaucoma , vol.19 , pp. 437-441
    • Kahook, M.Y.1    Ammar, D.A.2
  • 16
    • 84866514869 scopus 로고    scopus 로고
    • Impact of intravitreal injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
    • S. Karawya, D.G. Said, M.M. Salaheldin, and I. Zaky Impact of intravitreal injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina Middle East Afr. J. Ophthalmol. 15 2008 67 72
    • (2008) Middle East Afr. J. Ophthalmol. , vol.15 , pp. 67-72
    • Karawya, S.1    Said, D.G.2    Salaheldin, M.M.3    Zaky, I.4
  • 17
    • 79961239961 scopus 로고    scopus 로고
    • Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
    • M. Kubota-Taniai, T. Oshitari, M. Handa, T. Baba, J. Yotsukura, and S. Yamamoto Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma J. Clin. Ophthalmol 5 2011 1051 1055
    • (2011) J. Clin. Ophthalmol , vol.5 , pp. 1051-1055
    • Kubota-Taniai, M.1    Oshitari, T.2    Handa, M.3    Baba, T.4    Yotsukura, J.5    Yamamoto, S.6
  • 18
    • 57949101556 scopus 로고    scopus 로고
    • Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularisation? Graefes Arch
    • F. Lu, and R.A. Adelman Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularisation? Graefes Arch Clin. Exp. Ophthalmol. 247 2009 171 177
    • (2009) Clin. Exp. Ophthalmol. , vol.247 , pp. 171-177
    • Lu, F.1    Adelman, R.A.2
  • 20
    • 33646438886 scopus 로고    scopus 로고
    • Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment
    • R.K. Maturi, L.A. Bleau, and D.L. Wilson Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment Retina. 26 2006 270 274
    • (2006) Retina. , vol.26 , pp. 270-274
    • Maturi, R.K.1    Bleau, L.A.2    Wilson, D.L.3
  • 21
    • 79958706138 scopus 로고    scopus 로고
    • Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab
    • C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye 25 2011 661 672
    • (2011) Eye , vol.25 , pp. 661-672
    • Meyer, C.H.1    Holz, F.G.2
  • 22
    • 77957360007 scopus 로고    scopus 로고
    • VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro-possible participation of intracellular glutathione
    • Y. Miura, A. Kletter, and J. Roider VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro-possible participation of intracellular glutathione Invest. Ophthalmol. Vis. Sci. 51 2010 4848 4855
    • (2010) Invest. Ophthalmol. Vis. Sci. , vol.51 , pp. 4848-4855
    • Miura, Y.1    Kletter, A.2    Roider, J.3
  • 23
  • 32
    • 79951525187 scopus 로고    scopus 로고
    • Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease
    • M. Tolentino Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease Surv. Ophthalmol 56 2011 95 113
    • (2011) Surv. Ophthalmol , vol.56 , pp. 95-113
    • Tolentino, M.1
  • 33
    • 84859433783 scopus 로고    scopus 로고
    • Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration
    • J.J. Tseng, S.K. Vance, K.E. Della Torre, L.S. Mendonca, M.J. Cooney, J.M. Klancnik, J.A. Sorenson, and K.B. Freund Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration J. Glaucoma 21 2012 241 247
    • (2012) J. Glaucoma , vol.21 , pp. 241-247
    • Tseng, J.J.1    Vance, S.K.2    Della Torre, K.E.3    Mendonca, L.S.4    Cooney, M.J.5    Klancnik, J.M.6    Sorenson, J.A.7    Freund, K.B.8
  • 35
    • 47749112506 scopus 로고    scopus 로고
    • Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients
    • F. Ziemssen, M. Lüke, A. Messias, J. Beutel, O. Tatar, E. Zrenner, and K.U. Bartz-Schmidt Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients Int. Ophthalmol. 28 2008 101 109
    • (2008) Int. Ophthalmol. , vol.28 , pp. 101-109
    • Ziemssen, F.1    Lüke, M.2    Messias, A.3    Beutel, J.4    Tatar, O.5    Zrenner, E.6    Bartz-Schmidt, K.U.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.